First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

K Lindemann, R D Christensen, I Vergote, G Stuart, M A Izquierdo, J Kærn, H Havsteen, E Eisenhauer, M Ridderheim, A B Lopez, H Hirte, E Aavall-Lundquvist, E Vrdoljak, J Green, G B Kristensen

25 Citationer (Scopus)

Abstract

The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind23
Udgave nummer10
Sider (fra-til)2613-9
Antal sider7
ISSN0923-7534
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG'. Sammen danner de et unikt fingeraftryk.

Citationsformater